Biological predictors of treatment response in affective illness

Psychiatric Clinics of North America

Volumn 26, Issue 2, 2003, Pages 323-344

  Perlis, Roy H ^a   Iosifescu, Dan V ^a   Renshaw, Perry F ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CORTICOSTEROID; DEXAMETHASONE; HORMONE; LITHIUM; NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL MEDICINE; CLINICAL TRIAL; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; HORMONE BLOOD LEVEL; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MOOD DISORDER; NEUROENDOCRINOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHIATRIC TREATMENT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0037572064     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00112-0     Document Type: Review

References (125)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am 1996;19(2):179-200.
2. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10-7.
3. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13(5):305-11.
4. Mooney JJ, Schatzberg AF, Cole JO, et al. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. J Clin Psychopharmacol 1991;11(6):339-43.
5. Schildkraut JJ, Schatzberg AF, Samson JA, et al. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clin Neuropharmacol 1992;15(Suppl 1):323A-4A.
6. Hsiao JK, Agren H, Bartko JJ, et al. Monoamine neurotransmitter interactions and the prediction of antidepressant response. Arch Gen Psychiatry 1987;44(12):1078-83.
7. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38(1):15-22.
8. Ribeiro SC, Tandon R, Grunhaus L, et al. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150(11):1618-29.
9. Coryell W. DST abnormality as a predictor of course in major depression. J Affect Disord 1990;19(3):163-9.
10. Deutsch SI, Mastropaolo J, Hitri A. GABA-active steroids: endogenous modulators of GABA-gated chloride ion conductance. Clin Neuropharmacol 1992;15(5):352-64.
11. Maayan R, Yagorowski Y, Grupper D, et al. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiatry 2000;48(7):693-701.
12. Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000;25(8):765-71.
13. Berr C, Lafont S, Debuire B, et al. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A 1996;93(23):13410-5.
14. Morrison MF, Ten Have T, Freeman EW, et al. DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years. Biol Psychiatry 2001;50(9):705-11.
15. Bschor T, Canata B, Muller-Oerlinghausen B, et al. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 2001;64:261-5.
16. Alvarez E, Perez-Sola V, Perez-Blanco J, et al. Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord 1997;42:179-86.
17. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002;159(1):116-21.
18. Joffe RT. Peripheral thyroid hormone levels in treatment resistant depression. Biol Psychiatry 1999;45(8):1053-5.
19. Fava M, Labbate LA, Abraham ME, et al. Hypothyroidism and hyperthyroidism in major depression revisited. J Clin Psychiatry 1995;56(5):186-92.
20. Iosifescu DV, Howarth S, Alpert JE, et al. T3 blood levels and treatment outcome in depression. Int J Psychiatry Med 2001;31(4):367-73.
21. Langer G, Resch F, Aschauer H, et al. TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs. Neuropsychobiology 1984;11(4):213-8.
22. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin response to thyrotropinreleasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992;86(1):42-5.
23. Kirkegaard C, Faber J. Altered serum levels of thyroxine, triiodothyronines and diiodothyronines in endogenous depression. Acta Endocrinol (Copenh) 1981;96(2):199-207.
24. Targum SD. The application of serial neuroendocrine challenge studies in the management of depressive disorder. Biol Psychiatry 1983;18(1):3-19.
25. Krog-Meyer I, Kirkegaard C, Kijne B, et al. Prediction of relapse with the TRH test and prophylactic amitriptyline in 39 patients with endogenous depression. Am J Psychiatry 1984;141(8):945-8.
26. Amsterdam JD, Fava M, Maislin G, et al. TRH stimulation test as a predictor of acute and long-term antidepressant response in major depression. J Affect Disord 1996;38:165-72.
27. Siever LJ, Murphy DL, Slater S, et al. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984;34(11):1029-39.
28. Gorard DA, Taylor TM, Medbak SH, et al. Plasma prolactin, adrenocorticotrophic hormone and cortisol after administration of d-fenfluramine or placebo to healthy subjects. Int Clin Psychopharmacol 1993;8(2):123-8.
29. Van de Kar LD, Karteszi M, Bethea CL, et al. Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 1985;41(5):380-4.
30. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148(8):1009-15.
31. Cleare AJ, Murray RM, O'Keane V. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology 1996;14(5):349-54.
32. Park SB, Williamson DJ, Cowen PJ. Do the endocrine and subjective effects of d-fenfluramine predict response to selective serotonin reuptake inhibitors? Int Clin Psychopharmacol 1995;10(4):215-20.
33. Cleare AJ, Murray RM, O'Keane V. Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response. Biol Psychiatry 1998;44(7):555-61.
34. New AS, Woo-Ming A, Mitropoulou V, et al. Serotonin and the prediction of response time to fluoxetine in patients with mild depression. Psychiatry Res 1999;88(2):89-93.
35. Monteleone P, Catapano F, Di Martino S, et al. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment. Br J Psychiatry 1997;170:554-7.
36. Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997;42(7):546-52.
37. Hegerl U, Gallinat J, Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 2001;62:93-100.
38. Paige SR, Fitzpatrick DF, Kline JP, et al. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 1994;30(4):197-201.
39. Paige SR, Hendricks SE, Fitzpatrick DF, et al. Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull 1995;31(2):243-8.
40. Gallinat J, Bottlender R, Juckel G, et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 2000;148(4):404-11.
41. Bruneau N, Barthelemy C, Roux S, et al. Auditory evoked potential modifications according to clinical and biochemical responsiveness to fenfluramine treatment in children with autistic behavior. Neuropsychobiology 1989;21(1):48-52.
42. Carrillo-de-la-Pena MT, Mavrogiorgou P, Juckel G, et al. Loudness dependence of auditory evoked potentials in obsessive-compulsive disorder: a pilot study. Psychiatry Res 2000;93(3):209-16.
43. Hegerl U, Wulff H, Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: a replication study. Psychiatry Res 1992;44(3):181-90.
44. Hegerl U, Ulrich G, Muller-Oerlinghausen B. Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry 1987;20(5):213-6.
45. Malaspina D, Devanand DP, Krueger RB, et al. The significance of clinical EEG abnormalities in depressed patients treated with ECT. Convuls Ther 1994;10(4):259-66.
46. Leuchter AF, Daly KA, Rosenberg-Thompson S, et al. Prevalence and significance of electroencephalographic abnormalities in patients with suspected organic mental syndromes. J Am Geriatr Soc 1993;41(6):605-11.
47. Krystal AD, Weiner RD, Coffey CE. The ictal EEG as a marker of adequate stimulus intensity with unilateral ECT. J Neuropsychiatry Clin Neurosci 1995;7(3):295-303.
48. Nobler MS, Luber B, Moeller JR, et al. Quantitative EEG during seizures induced by electroconvulsive therapy: relations to treatment modality and clinical features. I. Global analyses. J ECT 2000;16(3):211-28.
49. Gangadhar BN, Subbakrishna DK, Janakiramaiah N, et al. Postseizure EEG fractal dimension of first ECT predicts antidepressant response at two weeks. J Affect Disord 1999;52:235-8.
50. Suppes T, Webb A, Carmody T, et al. Is postictal electrical silence a predictor of response to electroconvulsive therapy? J Affect Disord 1996;41(1):55-8.
51. Ulrich G, Haug HJ, Fahndrich E. Acute versus chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord 1994;32(3):213-7.
52. Knott VJ, Telner JI, Lapierre YD, et al. Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord 1996;39(3):175-84.
53. Cook IA, Leuchter AF, Uijtdehaage SH, et al. Altered cerebral energy utilization in late life depression. J Affect Disord 1998;49(2):89-99.
54. Cook IA, Leuchter AF, Witte E, et al. Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 1999;85(3):263-73.
55. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 2001;6(2):113-20.
56. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001;158(3):405-15.
57. Steingard RJ, Renshaw PF, Yurgelun-Todd D, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry 1996;35(3):307-11.
58. Kumar A, Jin Z, Bilker W, et al. Late-onset minor and major depression: early evidence for common neuroanatomical substrates detected by using MRI. Proc Natl Acad Sci U S A 1998;95(13):7654-8.
59. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386(6627):824-7.
60. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996;93(9):3908-13.
61. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157(1):115-8.
62. Parashos IA, Tupler LA, Blitchington T, et al. Magnetic-resonance morphometry in patients with major depression. Psychiatry Res 1998;84(1):7-15.
63. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998;9(9):2023-8.
64. Van Elst LT, Ebert D, Trimble MR. Hippocampus and amygdala pathology in depression. Am J Psychiatry 2001;158(4):652-3,
65. Kumar A, Bilker W, Jin Z, Udupa J. Atrophy and high-intensity lesions: complementary neurobiological mechanisms in late-life major depression. Neuropsychopharmacology 2000;22(3):264-74.
66. Lenze E, Cross D, McKeel D, et al. White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. Am J Psychiatry 1999;156(10):1602-7.
67. Awad IA, Spetzler RF, Hodak JA, et al. Incidental lesions noted on magnetic resonance imaging of the brain: prevalence and clinical significance in various age groups. Neurosurgery 1987;20(2):222-7.
68. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70(1):9-14.
69. Liao D, Cooper L, Cai J, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology 1997;16(3):149-62,
70. Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988;19(10):1285-8.
71. Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995;37(3):151-60.
72. Simpson SW, Jackson A, Baldwin RC, et al. 1997 IPA/Bayer Research Awards in Psychogeriatrics. Subcortical hyperintensities in late-life depression: acute response to treatment and neuropsychological impairment. Int Psychogeriatr 1997;9(3):257-75.
73. Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998;28(5):1015-26.
74. Krishnan KR, Hays JC, George LK, et al. Six-month outcomes for MRI-related vascular depression. Depress Anxiety 1998;8(4):142-6.
75. Iosifescu DV, Lyoo IK, Renshaw P, et al. Brain MRI white matter hyperintensities correlate with improved treatment outcome in depression. Presented at the Society of Biological Psychiatry Annual Convention. Philadelphia, PA. 2002.
76. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149(2):351-6.
77. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr Scand 1997;96(3):157-68.
78. Greenwald BS, Kramer-Ginsberg E, Krishnan RR, et al. MRI signal hyperintensities in geriatric depression. Am J Psychiatry 1996;153(9):1212-5.
79. Steffens DC, Helms MJ, Krishnan KR, et al. Cerebrovascular disease and depression symptoms in the cardiovascular health study. Stroke 1999;30(10):2159-66.
80. Stoll AL, Renshaw PF, Yurgelun-Todd DA, et al. Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 2000;48(6):505-17.
81. Altshuler LL, Curran JG, Hauser P, et al. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am J Psychiatry 1995;152(8):1139-44.
82. Yates WR, Wallace R. Cardiovascular risk factors in affective disorder. J Affect Disord 1987;12(2):129-34.
83. Strakowski SM, Wilson DR, Tohen M, et al. Structural brain abnormalities in firstepisode mania. Biol Psychiatry 1993;33:602-9.
84. Lyoo IK, Renshaw PF. Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 2002;51(3):195-207.
85. Sachs GS, Renshaw PF, Lafer B, et al. Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Biol Psychiatry 1995;38(7):422-8.
86. Henry ME, Moore CM, Kaufman MJ, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000;157(9):1506-8.
87. Strauss WL, Layton ME, Hayes CE, et al. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessivecompulsive disorder. Am J Psychiatry 1997;154(4):516-22.
88. Renshaw PF, Lafer B, Babb SM, et al. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1997;41(8):837-43.
89. Sonawalla SB, Renshaw PF, Moore CM, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 1999;156(10):1638-40.
90. Steingard RJ, Yurgelun-Todd DA, Hennen J, et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 2000;48(11):1053-61.
91. Frey R, Metzler D, Fischer P, et al. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 1998;32(6):411-20.
92. Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithiuminduced changes in frontal lobe myo-inositol and clinical response in manic depressive illness. Am J Psychiatry 1999;156(12):1902-8.
93. Ohara K, Isoda H, Suzuki Y, et al. Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar I affective disorder. Psychiatry Res 1998;84:55-60.
94. Winsberg ME, Sachs N, Tate DL, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000;47(6):475-81.
95. Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999;56(11):1043-7.
96. Auer DP, Putz B, Kraft E, et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47(4):305-13.
97. Moore CM, Christensen JD, Lafer B, et al. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997;154(1):116-8.
98. Volz HP, Rzanny R, Riehemann S, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 1998;248(6):289-95.
99. Kato T, Takahashi S, Shioiri T, et al. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992;26(4):223-30.
100. Kato T, Takahashi S, Shioiri T, et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994;31(2):125-33.
101. Renshaw PF, Parow AM, Hirashima F, et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001;158(12):2048-55.
102. Mayberg HS, Lewis PJ, Regenold W, et al. Paralimbic hypoperfusion in unipolar depression. J Nucl Med 1994;35(6):929-34.
103. Austin MP, Dougall N, Ross M, et al. Single photon emission tomography with 99mTcexametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum. J Affect Disord 1992;26(1):31-43.
104. Navarro V, Gasto C, Lomena F, et al. Frontal cerebral perfusion dysfunction in elderly late-onset major depression assessed by 99MTC-HMPAO SPECT. Neuroimag 2001;14:202-5.
105. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158(6):899-905.
106. Brody AL, Saxena S, Stoessel P, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001;58(7):631-40.
107. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9(3):471-81.
108. Ebert D, Feistel H, Barocka A. Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: a study with Tc-99m-HMPAO SPECT. Psychiatry Res 1991;40(4):247-51.
109. Wu JC, Gillin JC, Buchsbaum MS, et al. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry 1992;149(4):538-43.
110. Cohen RM, Gross M, Nordahl TE, et al. Preliminary data on the metabolic brain pattern of patients with winter seasonal affective disorder. Arch Gen Psychiatry 1992;49(7):545-52.
111. Videbeeh P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand 2000;101(1):11-20.
112. Baxter LR Jr, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46(3):243-50.
113. Kanaya T, Yonekawa M. Regional cerebral blood flow in depression. Jpn J Psychiatry Neurol 1990;44(3):571-6.
114. Hurwitz TA, Clark C, Murphy E, et al. Regional cerebral glucose metabolism in major depressive disorder. Can J Psychiatry 1990;35(8):684-8.
115. Martinot JL, Hardy P, Feline A, et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry 1990;147(10):1313-7.
116. Buchsbaum MS, Wu J, Siegel BV, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997;41(1):15-22.
117. Little JT, Ketter TA, Kimbrell TA, et al. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol Bull 1996;32(4):629-35.
118. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8(4):1057-61.
119. Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999;156(8):1149-58.
120. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre to post-treatment with paroxetine. Psychiatry Res 1999;91(3):127-39.
121. Saxena S, Brody AL, Ho ML, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder versus major depression. Arch Gen Psychiatry 2002;59(3):250-61.
122. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000;48(8):830-43.
123. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002;159(5):728-37.
124. Bremner JD, Innis RB, Salomon RM, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997;54(4):364-74.
125. Larisch R, Klimke A, Vosberg H, et al. In vivo evidence for the involvement of dopamineD2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimag 1997;5:251-60.